ClinicalTrials.gg
Active, not recruitingNCT05678673STELLAR-304Updated Jul 29, 2026

Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma

A Phase 3 interventional study of XL092 and Nivolumab in Non-Clear Cell Renal Cell Carcinoma, sponsored by Exelixis. Active, not recruiting at 163 sites in 25 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-29.

Sponsored by Exelixis · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
317
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing zanzalintinib in Carcinoma, Renal Cell — 10 open to participants now, 12 under way, 4 of them phase 3. zanzalintinib · Carcinoma, Renal Cell.

Enrollment
6th of 13
317 · median 140
Started
2023
the only one that year
Phase 3
4 of 13
3 open now
Primary completion
2026-12
later than 1 of 11 live
Registered
3rd of 13
by date
Lead sponsor
5 of 13
Exelixis

Among the 13 studies testing zanzalintinib in Carcinoma, Renal Cell, this one is the 6th largest by enrollment, is the only one that started in 2023, is one of 4 in phase 3, reaches primary completion later than 1 of the 11 other live ones, and was the 3rd registered.

Carcinoma, Renal Cell

2,039 studies on the registry are indexed under Carcinoma, Renal Cell; 396 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

10 of the 13 studies testing zanzalintinib in Carcinoma, Renal Cell are open now, in 12 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About zanzalintinib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 309 Carcinoma, Renal Cell studies recruiting now, 256 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing zanzalintinib in Carcinoma, Renal Cell, or all of them as a file.
02

Study summary

This is a multicenter, randomized (2:1), open-label, controlled Phase 3 trial of XL092 in combination with nivolumab versus sunitinib in subjects with unresectable, locally advanced or metastatic nccRCC who have not received prior systemic anticancer therapy.

03

Conditions studied

  • Non-Clear Cell Renal Cell Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed nccRCC that is unresectable, advanced or . Histologic subtypes including papillary, unclassified, and translocation-associated are allowed. Among the eligible histologic subtypes, sarcomatoid features are allowed.
  • according to v1.1 as determined by the Investigator.
  • Available archival tumor material.
  • Recovery to baseline or ≤ Grade 1 per v5 from AE(s) related to any prior treatments unless AE(s) are deemed clinically nonsignificant by the Investigator and/or stable on supportive therapy.
  • Age 18 years or older on the day of consent.
  • Performance Status (KPS) ≥ 70%.
  • Adequate organ and marrow function within 14 days prior to randomization.
  • Sexually active fertile subjects and their partners must agree to use highly effective methods of .
  • Female subjects of must not be pregnant at screening.

Exclusion criteria

Exclusion Criteria:

  • Chromophobe, renal medullary carcinoma, and pure collecting duct histologic subtypes of nccRCC.
  • Prior systemic anticancer therapy for unresectable locally advanced or nccRCC including agents.

    • Note: One prior systemic therapy, including therapy and excluding sunitinib, is allowed for completely resected RCC and if recurrence occurred at least 6 months after the last dose of adjuvant therapy.
  • Radiation therapy for bone metastases within 2 weeks, any other radiation therapy within 4 weeks prior to randomization.
  • Known or cranial epidural disease unless adequately treated with radiotherapy (including radiosurgery) or surgically removed and stable for at least 4 weeks before randomization.
  • Concomitant anticoagulation with oral anticoagulants and inhibitors. Subjects who are receiving oral anticoagulants at the time of screening must be transitioned to LMWH prior to randomization. Subjects who require treatment with platelet inhibitors are not eligible.
  • Major surgery (eg, GI surgery, removal or of brain metastasis) within 8 weeks prior to randomization. Prior laparoscopic nephrectomy within 4 weeks prior to randomization. Minor surgery (eg, simple excision, tooth extraction) within 10 days before randomization. Complete wound healing from major or minor surgery must have occurred at least prior to randomization.

    • Note: Fresh tumor biopsies should be performed at least 7 days before randomization. Subjects with ongoing complications from prior surgical procedures, including biopsies, are not eligible.
  • interval calculated by the Fridericia formula (QTcF) > 480 ms per (ECG) within 14 days before randomization.
  • Pregnant or lactating females.
  • Administration of a live, attenuated vaccine within 30 days before randomization.

    • Note: If feasible, approved non- for SARS-CoV-2 should be administered at least 2 weeks before randomization.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
317 participants (actual)

Study arms

  • Experimental
    XL092 + Nivolumab

    Subjects with advanced or metastatic nccRCC will receive XL092 + nivolumab

    Drug: XL092 · Drug: Nivolumab

  • Active comparator
    Sunitinib Malate

    Subjects with advanced or metastatic nccRCC will receive an active comparator of sunitinib

    Drug: Sunitinib Malate

Interventions

  • DrugXL092

    Specified doses on specified days

  • Specified doses on specified days

    Also known as: Opdivo®

  • Specified doses on specified days

    Also known as: Sutent®

06

What researchers measure

Primary outcomes

  1. Duration of Progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1), by Blinded Independent Radiology Committee (BIRC)

    Defined as the time from randomization to the earlier of either radiographic PD per RECIST 1.1 as determined by the BIRC or death from any cause

    Time frame: Approximately 27 months after the first subject is randomized

  2. Objective response rate (ORR) as assessed by BIRC per RECIST 1.1

    Defined as the proportion of subjects with the best overall response of complete response (CR) or partial response (PR) per RECIST 1.1 as determined by the BIRC that is confirmed at a follow-up assessment ≥ 28 days later

    Time frame: Up to 24 months after the first subject is randomized

Secondary outcomes

  1. Duration of Overall Survival (OS)

    Defined as the time from randomization to death due to any cause

    Time frame: Approximately 46 months after the first subject is randomized

07

Study locations

163 sites
  • Exelixis Clinical Site #1
    Duarte, California 91010, United States
  • Exelixis Clinical Site #164
    Newport Beach, California 92663, United States
  • Exelixis Clinical Site #162
    San Francisco, California 94115, United States
  • Exelixis Clinical Site #163
    Aurora, Colorado 80045, United States
  • Exelixis Clinical Site #55
    Jacksonville, Florida 32209, United States
  • Exelixis Clinical Site #161
    Buffalo, New York 14263, United States
  • Exelixis Clinical Site #58
    New York, New York 10029, United States
  • Exelixis Clinical Site #15
    New York, New York 10065, United States
  • Exelixis Clinical Site #42
    Cleveland, Ohio 44106, United States
  • Exelixis Clinical Site #31
    Dallas, Texas 75246, United States
  • Exelixis Clinical Site #88
    Pilar, Buenos Aires B1629ODT, Argentina
  • Exelixis Clinical Site #89
    Viedma, Río Negro Province R8500ACE, Argentina
  • Exelixis Clinical Site #44
    Buenos Aires, B7600FZO, Argentina
  • Exelixis Clinical Site #35
    CABA, C1419GEP, Argentina
  • Exelixis Clinical Site #90
    Córdoba, X5004BAL, Argentina
  • Exelixis Clinical Site #51
    Santa Fe, 2000, Argentina
  • Exelixis Clinical Site #94
    Albury, New South Wales 2640, Australia
  • Exelixis Clinical Site #97
    Camperdown, New South Wales 3021, Australia
  • Exelixis Clinical Site #98
    Liverpool, New South Wales 2170, Australia
  • Exelixis Clinical Site #95
    Macquarie, New South Wales 2109, Australia
  • Exelixis Clinical Site #92
    Sydney, New South Wales 2145, Australia
  • Exelixis Clinical Site #93
    Waratah, New South Wales 2298, Australia
  • Exelixis Clinical Site #99
    Douglas, Queensland 4814, Australia
  • Exelixis Clinical Site #100
    Elizabeth Vale, South Australia 5112, Australia
  • Exelixis Clinical Site #91
    Box Hill, Victoria 3128, Australia
  • Exelixis Clinical Site #96
    St Albans, Victoria 3021, Australia
  • Exelixis Clinical Site #14
    Chermside, 4032, Australia
  • Exelixis Clinical Site #29
    South Brisbane, 4101, Australia
  • Exelixis Clinical Site #102
    Porto Alegre, Rio Grande do Sul 90035-903, Brazil
  • Exelixis Clinical Site #68
    Barretos, 14784 400, Brazil
  • Exelixis Clinical Site #39
    Itajaí, 88301-220, Brazil
  • Exelixis Clinical Site #69
    Passo Fundo, 99010-090, Brazil
  • Exelixis Clinical Site #70
    Porto Alegre, 90110-270, Brazil
  • Exelixis Clinical Site #78
    Porto Alegre, 91350-200, Brazil
  • Exelixis Clinical Site #87
    Santo André, 09060-870, Brazil
  • Exelixis Clinical Site #50
    São José do Rio Preto, 15090-000, Brazil
  • Exelixis Clinical Site #101
    São Paulo, 01246-000, Brazil
  • Exelixis Clinical Site #81
    São Paulo, 01323-001, Brazil
  • Exelixis Clinical Site #85
    São Paulo, 01323-903, Brazil
  • Exelixis Clinical Site #43
    São Paulo, 17210-120, Brazil
  • Exelixis Clinical Site #104
    Plovdiv, 4004, Bulgaria
  • Exelixis Clinical Site #105
    Sofia, 1404, Bulgaria
  • Exelixis Clinical Site #103
    Sofia, 1431, Bulgaria
  • Exelixis Clinical Site #53
    Providencia, 7520378, Chile
  • Exelixis Clinical Site #106
    Santiago, 7500921, Chile
  • Exelixis Clinical Site #108
    Santiago, 7520378, Chile
  • Exelixis Clinical Site #109
    Santiago, 8241479, Chile
  • Exelixis Clinical Site #107
    Santiago, 8420383, Chile
  • Exelixis Clinical Site #111
    Rijeka, 51000, Croatia
  • Exelixis Clinical Site #110
    Zagreb, 10000, Croatia
  • Exelixis Clinical Site #61
    Brno, 602 00, Czechia
  • Exelixis Clinical Site #112
    Olomouc, 77900, Czechia
  • Exelixis Clinical Site #27
    Prague, 140 59, Czechia
  • Exelixis Clinical Site #86
    Prague, 150 06, Czechia
  • Exelixis Clinical Site #71
    Helsinki, 00290, Finland
  • Exelixis Clinical Site #115
    Angers, Maine Et Loire 49933, France
  • Exelixis Clinical Site #74
    Caen, 14076, France
  • Exelixis Clinical Site #66
    Clermont-Ferrand, 63011, France
  • Exelixis Clinical Site #40
    Créteil, 94010, France
  • Exelixis Clinical Site #38
    Le Mans, 72000, France
  • Exelixis Clinical Site #114
    Lille, 59020, France
  • Exelixis Clinical Site #113
    Lyon, 08Rhone69373, France
  • Exelixis Clinical Site #36
    Marseille, 13385, France
  • Exelixis Clinical Site #12
    Paris, 75013, France
  • Exelixis Clinical Site #67
    Paris, 75475, France
  • Exelixis Clinical Site #76
    Pierre-Bénite, 69310, France
  • Exelixis Clinical Site #59
    Reims, 51726, France
  • Exelixis Clinical Site #28
    Rennes, 35042, France
  • Exelixis Clinical Site #41
    Strasbourg, 67200, France
  • Exelixis Clinical Site #65
    Suresnes, 92150, France
  • Exelixis Clinical Site #116
    Frankfurt am Main, Hesse 60590, Germany
  • Exelixis Clinical Site #79
    Eisleben Lutherstadt, 06295, Germany
  • Exelixis Clinical Site #117
    Hamburg, 22763, Germany
  • Exelixis Clinical Site #118
    Athens, 11528, Greece
  • Exelixis Clinical Site #119
    Athens, 12462, Greece
  • Exelixis Clinical Site #123
    Athens, 12462, Greece
  • Exelixis Clinical Site #121
    Thessaloniki, 54622, Greece
  • Exelixis Clinical Site #120
    Thessaloniki, 56403, Greece
  • Exelixis Clinical Site #122
    Tripoli, 22131, Greece
  • Exelixis Clinical Site #124
    Hong Kong, Hong Kong
  • Exelixis Clinical Site #125
    Hong Kong, Hong Kong
  • Exelixis Clinical Site #128
    Budapest, 1082, Hungary
  • Exelixis Clinical Site #127
    Budapest, 1122, Hungary
  • Exelixis Clinical Site #126
    Debrecen, 4032, Hungary
  • Exelixis Clinical Site #130
    Rozzano, Milano 20089, Italy
  • Exelixis Clinical Site #131
    Candiolo, Torino 10060, Italy
  • Exelixis Clinical Site #7
    Arezzo, 52100, Italy
  • Exelixis Clinical Site #132
    Bari, 70124, Italy
  • Exelixis Clinical Site #26
    Brescia, 25123, Italy
  • Exelixis Clinical Site #19
    Meldola, 47014, Italy
  • Exelixis Clinical Site #129
    Milan, 20132, Italy
  • Exelixis Clinical Site #30
    Naples, 80131, Italy
  • Exelixis Clinical Site #37
    Pavia, 27100, Italy
  • Exelixis Clinical Site #63
    Pisa, 56126, Italy
  • Exelixis Clinical Site #48
    Reggio Emilia, 42123, Italy
  • Exelixis Clinical Site #60
    Roma, 00168, Italy
  • Exelixis Clinical Site #72
    San Giovanni Rotondo, 71013, Italy
  • Exelixis Clinical Site #17
    Verona, 37134, Italy
  • Exelixis Clinical Site #54
    Kuala Lumpur, 50586, Malaysia
  • Exelixis Clinical Site #24
    Kuala Lumpur, 59100, Malaysia

Showing the first 100 of 163 sites across 25 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Pal SK, Powles T, Kanesvaran R, Molina-Cerrillo J, Feldman DR, Barata P, Liu M, Bhatt A, Wang Z, Nandoskar P, Suarez C. STELLAR-304: a phase III study of zanzalintinib (XL092) plus nivolumab in advanced non-clear cell renal cell carcinoma. Future Oncol. 2025 Mar;21(7):787-794. doi: 10.1080/14796694.2025.2458395. Epub 2025 Feb 26. PubMed 40008409 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2023 (actual). Primary completion is estimated for Dec 2026, 47 months after the start.

Of 35 industry-sponsored phase 3 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 59. This study's planned 47 months is close to that.

Counting every sponsor, half of 61 studies reached it within 56 months; a quarter within 42 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2022
First posted
Jan 10, 2023
StartActual
Jan 1, 2023
Primary completionEst.
Dec 15, 2026
CompletionEst.
Jun 30, 2028
Last update
Jul 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05678673
Lead sponsor
Exelixis
Responsible party
Sponsor
First posted
Jan 10, 2023
Start date
Jan 1, 2023
Primary completion
Dec 15, 2026 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Jul 29, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zanzalintinib

Start the discussion